Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CAPSULE
**Dosage and administration :** Adults: For Serious Infections: 150 mg – 300 mg / 6-hourly. For More Severe Infections: 450 mg / 6-hourly. Children > 1 month : For Serious Infections : 8 – 16 mg/kg body weight/day given in 3 – 4 divided doses. For More Severe Infections : 16 – 20 mg/kg body weight/day given in 3 – 4 divided doses.
ORAL
Medical Information
**Indications :** Serious infections caused by organisms sensitive to CLIMADAN include upper and lower respiratory tract infections, otitis media, skin infections, osteomyelitis, endocarditis, anaerobic infections and others. It is also indicated for prophylaxis of postoperative infections caused by anaerobic bacteria.
**Contraindications :** Patients hypersensitive to lincomycin and clindamycin. Patients with diarrhoea, liver and kidney functions disturbances. Atopic individuals, e.g. the asthmatic and allergic patients. It is not indicated for meningitis and in the treatment of mild infections caused by bacteria and viruses.
J01FF01
clindamycin
Manufacturer Information
ZYFAS PHARMA PTE. LTD.
PT. DANKOS FARMA
Active Ingredients
Documents
Package Inserts
Climadan 150 PI.pdf
Approved: June 17, 2022